Elsevier

Annals of Oncology

Volume 15, Issue 9, September 2004, Pages 1339-1343
Annals of Oncology

Gastrointestinal tumors
Gemcitabine combined with oxaliplatin (GEMOX) in advanced biliary tract adenocarcinoma: a GERCOR study

https://doi.org/10.1093/annonc/mdh351Get rights and content
Under an Elsevier user license
open archive

ABSTRACT

Background

Since gemcitabine–oxaliplatin (GEMOX) has been used in pancreatic adenocarcinoma, we studied its activity and tolerability in advanced biliary tract adenocarcinoma (ABTA).

Patients and methods

Consecutive adult patients with confirmed ABTA were recruited from four centers. Those in group A had performance status (PS) 0–2, bilirubin <2.5× normal and received GEMOX as first-line chemotherapy. Those in group B had PS >2 and/or bilirubin >2.5× normal and/or prior chemotherapy. All received gemcitabine 1000 mg/m2 as a 10 mg/m2/min infusion on day 1, followed by oxaliplatin 100 mg/m2 as a 2-h infusion on day 2, every 2 weeks.

Results

Tumor sites were gallbladder (19), extrahepatic bile ducts (5), ampulla of vater (3) and intrahepatic bile ducts (29). Results for group A (n=33) were: objective response 36% [95% confidence interval (CI) 18.7% to 52.3%], stable disease 26%, progressive disease 39%, median progression-free survival (PFS) 5.7 months and overall survival (OS) 15.4 months. Results for group B (n=23) were: objective response 22% (95% CI 6.5% to 37.4%), stable disease 30%, progressive disease 48%, PFS 3.9 months and OS 7.6 months. National Cancer Institute Common Toxicity Criteria grade 3–4 toxicities were neutropenia 14% of patients, thrombocytopenia 9%, nausea/vomiting 5% and peripheral neuropathy 7%.

Conclusion

The GEMOX combination is active and well tolerated in ABTA.

Keywords

advanced biliary tract adenocarcinoma
chemotherapy
gemcitabine
oxaliplatin

Cited by (0)